Lumenis' new Novus 3000 laser gets FDA approval to treat retinal conditions

By E. Janene Geiss

Philadelphia, Nov. 29 - Lumenis Ltd. announced Tuesday that it received clearance from the U.S. Food and Drug Administration to market the new Novus 3000, a 532 nm diode-pumped solid-state photocoagulator.

The lasers treat several retinal conditions that can lead to vision loss and blindness, including proliferative diabetic retinopathy, retinopathy of prematurity, retinal tears and detachment and retinal vein occlusion, according to a company news release.

Estimates suggest that more than 30 million people suffer from these conditions. With the aging population, these numbers are expected to increase, officials said.

"Lumenis has provided the ophthalmic industry with innovative technology since 1970, when we introduced the world's 'first' laser photocoagulator," said Avner Raz, president and chief executive officer, in the release.

"With the addition of our Novus 3000, we once again demonstrate our commitment to helping patients and their ophthalmologists protect and preserve sight," he said.

Its predecessor system, the Lumenis' Novus 2000, earned a solid reputation for its design and ease-of-use, officials said.

Lumenis said it also received FDA clearance to market the Coaxial Multicolor LIO for the delivery of photocoagulator laser energy during ophthalmic surgery. Lumenis said it was the world's first and only technology of its kind.

Compatible with Lumenis' Novus 3000 and Novus Varia, the Coaxial Multicolor LIO's main benefits include superior performance, integrated multi-wavelength eye safety filters and ease-of-use, officials said.

This coaxial multicolor technology provides precise laser delivery with repeatable outcomes, as well as maximum treatment options and physician safety, officials said.

Based in Yokneam, Israel, Lumenis is a developer, manufacturer and seller of laser and light-based devices for medical, aesthetic, ophthalmic, dental and veterinary applications.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.